Prevalence of storage lower urinary tract symptoms in male patients attending Spanish urology office. Urinary urgency as predictor of quality of life

Autor: Cambronero Santos, J., Errando Smet, C.

Publikováno v: In Actas Urológicas Españolas (English Edition) December 2016 40(10):621-627

Mirabegron Vs Placebo Add-on Therapy in Men With Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Safety Analysis From the Randomized, Phase 4 PLUS Study.

Autor: Herschorn S; Department of Surgery/Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL; Department of Urology, Infanta Leonor Hospital, Madrid, Spain; Department of Urology, Royal Berkshire Hospital, Reading, United Kingdom; Astellas Pharma Global Development Inc., Northbrook, IL; Astellas Pharma Europe Ltd., Chertsey, United Kingdom; Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY. Electronic address: Sender.Herschorn@sunnybrook.ca., McVary KT; Department of Surgery/Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL; Department of Urology, Infanta Leonor Hospital, Madrid, Spain; Department of Urology, Royal Berkshire Hospital, Reading, United Kingdom; Astellas Pharma Global Development Inc., Northbrook, IL; Astellas Pharma Europe Ltd., Chertsey, United Kingdom; Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY., Cambronero Santos J; Department of Surgery/Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL; Department of Urology, Infanta Leonor Hospital, Madrid, Spain; Department of Urology, Royal Berkshire Hospital, Reading, United Kingdom; Astellas Pharma Global Development Inc., Northbrook, IL; Astellas Pharma Europe Ltd., Chertsey, United Kingdom; Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY., Foley S; Department of Surgery/Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL; Department of Urology, Infanta Leonor Hospital, Madrid, Spain; Department of Urology, Royal Berkshire Hospital, Reading, United Kingdom; Astellas Pharma Global Development Inc., Northbrook, IL; Astellas Pharma Europe Ltd., Chertsey, United Kingdom; Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY., Kristy RM; Department of Surgery/Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL; Department of Urology, Infanta Leonor Hospital, Madrid, Spain; Department of Urology, Royal Berkshire Hospital, Reading, United Kingdom; Astellas Pharma Global Development Inc., Northbrook, IL; Astellas Pharma Europe Ltd., Chertsey, United Kingdom; Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY., Choudhury N; Department of Surgery/Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL; Department of Urology, Infanta Leonor Hospital, Madrid, Spain; Department of Urology, Royal Berkshire Hospital, Reading, United Kingdom; Astellas Pharma Global Development Inc., Northbrook, IL; Astellas Pharma Europe Ltd., Chertsey, United Kingdom; Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY., Hairston J; Department of Surgery/Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL; Department of Urology, Infanta Leonor Hospital, Madrid, Spain; Department of Urology, Royal Berkshire Hospital, Reading, United Kingdom; Astellas Pharma Global Development Inc., Northbrook, IL; Astellas Pharma Europe Ltd., Chertsey, United Kingdom; Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY., Kaplan SA; Department of Surgery/Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL; Department of Urology, Infanta Leonor Hospital, Madrid, Spain; Department of Urology, Royal Berkshire Hospital, Reading, United Kingdom; Astellas Pharma Global Development Inc., Northbrook, IL; Astellas Pharma Europe Ltd., Chertsey, United Kingdom; Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY.

Publikováno v: Urology [Urology] 2021 Jan; Vol. 147, pp. 235-242. Date of Electronic Publication: 2020 Oct 10.

Prevalencia de síntomas del tracto urinario inferior de llenado en pacientes varones que acuden a consulta de urología en España. La urgencia urinaria como predictor de calidad de vida

Autor: Cambronero Santos, J., Errando Smet, C.

Publikováno v: Actas Urológicas Españolas; 20240101, Issue: Preprints

Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).

Autor: Kaplan SA; Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, New York., Herschorn S; Department of Surgery/Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., McVary KT; Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, Illinois., Staskin D; Division of Urology, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts., Chapple C; Department of Urology, Royal Hallamshire Hospital, Sheffield, UK., Foley S; Department of Urology, Royal Berkshire Hospital, Reading, UK., Cambronero Santos J; Department of Urology, Infanta Leonor Hospital, Madrid, Spain., Kristy RM; Astellas Pharma Global Development Inc., Northbrook, Illinois., Choudhury N; Astellas Pharma Europe Ltd., Chertsey, UK., Hairston J; Astellas Pharma Global Development Inc., Northbrook, Illinois., Schermer CR; Astellas Pharma Global Development Inc., Northbrook, Illinois.

Publikováno v: The Journal of urology [J Urol] 2020 Jun; Vol. 203 (6), pp. 1163-1171. Date of Electronic Publication: 2020 Jan 02.

Ligand–Receptor Interactions and Structure–Function Relationships in Off-Target Binding of the β 3 -Adrenergic Agonist Mirabegron to α 1A -Adrenergic Receptors.

Autor: Huang, Ru¹ (AUTHOR) sysmhr27@hotmail.com, Yu, Qingfeng¹ (AUTHOR) yuqf2010@gmail.com, Tamalunas, Alexander² (AUTHOR) alexander.tamalunas@med.uni-muenchen.de, Stief, Christian G.² (AUTHOR), Hennenberg, Martin^2,3 (AUTHOR) martin.hennenberg@med.uni-muenchen.de

Publikováno v: International Journal of Molecular Sciences. Jul2024, Vol. 25 Issue 13, p7468. 19p.